The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The head office and logo of Valeant Pharmaceutical are pictured in Montreal on Monday May 27, 2013.
The head office and logo of Valeant Pharmaceutical are pictured in Montreal on Monday May 27, 2013.
(Ryan Remiorz/CP)

SEAN SILCOFF

As Valeant's profile rises, tax avoidance will raise ire

ROB Insight is a premium commentary product offering rapid analysis of business and economic news, corporate strategy and policy, published throughout the business day. Visit the ROB Insight homepage for analysis available only to subscribers.

With its proposed takeover of Bausch & Lomb Inc., Canadian drug company Valeant Pharmaceuticals International Inc. continues its march toward big-time status. The deal will create a company with upward of $8-billion in revenue and an appetite for more; CEO Michael Pearson said early this year he expected the serially acquisitive company would reach the $10-billion mark “in the foreseeable future.”